A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
DS was the most frequent serious TRAE. Although antileukemic activity was observed, no objective responses were achieved, and disease progression frequently occurred within 1 to 2 treatment cycles. Blast reductions were reported across cytogenetic and mutational profiles, coupled with myeloid differentiation via BRG1/BRM inhibition. This novel mechanism warrants further investigation of FHD-286 in combination with other agents in myeloid malignancies.
Authors
- Kim Horrigan
- Michael P. Collins (ORCID: https://orcid.org/0000-0002-1806-6775)
- Courtney Denton Dinardo (ORCID: https://orcid.org/0000-0001-9003-0390)
- Dillon Corrigan (ORCID: https://orcid.org/0000-0002-5390-0139)
- GiNell Elliott
- Gromoslaw A. Smolen (ORCID: https://orcid.org/0000-0003-0136-4685)
- Caroline Almon
- Caitlin Patriquin
- Michael Robert Savona (ORCID: https://orcid.org/0000-0003-3763-5504)
- Murphy Hentemann
- Sanam Loghavi (ORCID: https://orcid.org/0000-0001-8980-3202)
- Ashwin Kishtagari (ORCID: https://orcid.org/0000-0003-1149-4571)
- Katie D’Aco (ORCID: https://orcid.org/0000-0003-3215-7697)
- Eytan M. Stein (ORCID: https://orcid.org/0000-0001-8992-9390)
- David L. Lahr (ORCID: https://orcid.org/0000-0001-6283-0286)
- Kapil N. Bhalla (ORCID: https://orcid.org/0000-0001-5209-5126)
- Virna Schuck
- Amir T. Fathi (ORCID: https://orcid.org/0000-0002-5848-6221)
- Salah Nabhan
- Jessica Piel
- Paul Martin (ORCID: https://orcid.org/0009-0002-2598-4520)
- Alfonso Quintás‐Cardama (ORCID: https://orcid.org/0000-0002-4623-8917)
- Samuel Agresta
- Alexis Khalil (ORCID: https://orcid.org/0009-0008-9231-7641)
- Denice Hickman
- Tina Zhao
- Kathleen Healy
- Sarah A. Reilly
- Kelly Lyons
- Mia Bosinger
Institutions
- Boston Biomedical Research Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Vanderbilt University (US)
- University of Massachusetts Boston (US)
- Massachusetts General Hospital (US)
- Agios Pharmaceuticals (United States) (US)
- Quantum Diamond Technologies (United States) (US)
- Relay Therapeutics (United States) (US)
- Novartis (United States) (US)
- Certara (United States) (US)
- Io Therapeutics (United States) (US)
- International Drug Development (FR)
- Foghorn Therapeutics (United States) (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3790
- Citations
- 8
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 14.16